Coherus Oncology
CHRS
163 hedge funds and large institutions have $536M invested in Coherus Oncology in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 65 reducing their positions, and 18 closing their positions.
180% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $372K
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
1% more funds holding
Funds holding: 161 → 163 (+2)
2.57% less ownership
Funds ownership: 101.09% → 98.52% (-2.6%)
14% less capital invested
Capital invested by funds: $623M → $536M (-$86.2M)
29% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 65
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$4.45M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$4.22M |
| 3 |
BlackRock
New York
|
+$2.45M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.16M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$5.34M |
| 2 |
JP Morgan Chase
New York
|
-$4.05M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.56M |
| 4 |
Millennium Management
New York
|
-$2.52M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIG
176
Sargent Investment Group
Bethesda,
Maryland
| – | -$88.7K | -11,200 | Closed |
|
|
MLICM
177
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$33.7K | -4,249 | Closed |
|
|
SWA
178
Sutton Wealth Advisors
Tampa,
Florida
| – | -$27.5K | -3,473 | Closed |
|
|
IA
179
IFP Advisors
Tampa,
Florida
| – | -$16K | -1,000 | Closed |
|
180
Rockefeller Capital Management
New York
| – | -$3K | -449 | Closed |
|
|
QCG
181
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$166 | -21 | Closed |
|
CHRS Hedge Fund Activity: Q1 2023 in Review
163 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2023, worth a combined $536M — down 14% from $623M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CHRS positions and 18 closed out — a net gain of 3 holders — while 46 added to existing stakes and 65 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $4.45M. The largest seller was State Street, cutting an estimated $5.34M.
- 163 institutional investors held Coherus Oncology (CHRS) as of Q1 2023, up from 161 in Q4 2022.
- Funds reported $536M of Coherus Oncology stock for Q1 2023, down 14% quarter-over-quarter.
- 21 funds opened new Coherus Oncology positions in Q1 2023 and 18 closed out, a net change of +3 holders.
- The largest Coherus Oncology buyer in Q1 2023 was Marshall Wace, an estimated $4.45M added.
- The largest Coherus Oncology seller in Q1 2023 was State Street, an estimated $5.34M sold.
Based on aggregated 13F filings for Q1 2023.